Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction
| Autor: | Sercan Okutucu, Nurbanu Bursa, S.G. Fatihoglu, Begum Yetis Sayin, Ali Oto, Cengiz Sabanoglu, Hakan Aksoy |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Angiotensins medicine.drug_class Tetrazoles 030204 cardiovascular system & hematology Sacubitril Ventricular Function Left 03 medical and health sciences 0302 clinical medicine Internal medicine Heart rate medicine Natriuretic peptide Humans 030212 general & internal medicine Aged Heart Failure Ejection fraction Receptors Angiotensin medicine.diagnostic_test business.industry Aminobutyrates Atrial fibrillation Stroke Volume Middle Aged medicine.disease Drug Combinations Valsartan Heart failure Cardiology Neprilysin Cardiology and Cardiovascular Medicine business Electrocardiography medicine.drug |
| Zdroj: | Herz. 46(Suppl 1) |
| ISSN: | 1615-6692 |
| Popis: | Angiotensin receptor neprilysin inhibitors (ARNI; sacubitril/valsartan combination) decrease morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Increased P‑wave duration and P‑wave dispersion (Pd) reflect prolongation of atrial conduction and correlate with atrial fibrillation. Here, we aimed to assess the effects of switching from valsartan to ARNI treatment on the basis of P‑wave indices. A total of 28 patients with HFrEF (mean age, 64.8 ± 10.6 years; 18 males, 78.6% ischemic etiology) were included. All patients had New York Heart Association functional class II–III, left ventricular ejection fraction ≤35%, and had been switched from valsartan to ARNI treatment. Standard 12-lead electrocardiograms from patients on valsartan treatment and electrocardiograms 1 month after ARNI treatment were analyzed; heart rate, maximum P‑wave duration (Pmax), minimum P‑wave duration (Pmin), and Pd were calculated. Minnesota Living with Heart Failure Questionnaire (MLWHFQ) scores and N‑terminal pro-brain natriuretic peptide (NT-proBNP) values were recorded. The Pmax (135.6 ± 32.1 ms vs. 116.1 ± 14.1 ms, p = 0.041) and Pd (33.6 ± 7.9 vs. 28.6 ± 5.3, p = 0.006) values were significantly reduced after ARNI treatment. Furthermore, ARNI treatment was associated with an improvement in MLWHFQ scores (31.2 ± 6.2 ms vs. 23.2 ± 7.0 ms, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink